Amin Khademi1, Denis Saure2, Andrew Schaefer3, Kimberly Nucifora4, R Scott Braithwaite4, Mark S Roberts5. 1. Department of Industrial Engineering, Clemson University, Clemson, SC, USA. Electronic address: Khademi@clemson.edu. 2. Department of Industrial Engineering, University of Chile, Santiago, Chile. 3. Department of Industrial Engineering, University of Pittsburgh, Pittsburgh, PA, USA. 4. Section of Value and Comparative Effectiveness, NYU School of Medicine, New York, NY, USA. 5. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Industrial Engineering, University of Pittsburgh, Pittsburgh, PA, USA; Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.
Abstract
BACKGROUND: The effects of antiretroviral treatment on the HIV epidemic are complex. HIV-infected individuals survive longer with treatment, but are less likely to transmit the disease. The standard coverage measure improves with the deaths of untreated individuals and does not consider the fact that some individuals may acquire the disease and die before receiving treatment, making it susceptible to overestimating the long-run performance of antiretroviral treatment programs. OBJECTIVE: The objective was to propose an alternative coverage definition to better measure the long-run performance of HIV treatment programs. METHODS: We introduced cumulative incidence-based coverage as an alternative to measure an HIV treatment program's success. To numerically compare the definitions, we extended a simulation model of HIV disease and treatment to represent a dynamic population that includes uninfected and HIV-infected individuals. Also, we estimated the additional resources required to implement various treatment policies in a resource-limited setting. RESULTS: In a synthetic population of 600,000 people of which 44,000 (7.6%) are infected, and eligible for treatment with a CD4 count of less than 500 cells/mm(3), assuming a World Health Organization (WHO)-defined coverage rate of 50% of eligible people, and treating these individuals with a single treatment regimen, the gap between the current WHO coverage definition and our proposed one is as much as 16% over a 10-year planning horizon. CONCLUSIONS: Cumulative incidence-based definition of coverage yields a more accurate representation of the long-run treatment success and along with the WHO and other definitions of coverage provides a better understanding of the HIV treatment progress.
BACKGROUND: The effects of antiretroviral treatment on the HIV epidemic are complex. HIV-infected individuals survive longer with treatment, but are less likely to transmit the disease. The standard coverage measure improves with the deaths of untreated individuals and does not consider the fact that some individuals may acquire the disease and die before receiving treatment, making it susceptible to overestimating the long-run performance of antiretroviral treatment programs. OBJECTIVE: The objective was to propose an alternative coverage definition to better measure the long-run performance of HIV treatment programs. METHODS: We introduced cumulative incidence-based coverage as an alternative to measure an HIV treatment program's success. To numerically compare the definitions, we extended a simulation model of HIV disease and treatment to represent a dynamic population that includes uninfected and HIV-infected individuals. Also, we estimated the additional resources required to implement various treatment policies in a resource-limited setting. RESULTS: In a synthetic population of 600,000 people of which 44,000 (7.6%) are infected, and eligible for treatment with a CD4 count of less than 500 cells/mm(3), assuming a World Health Organization (WHO)-defined coverage rate of 50% of eligible people, and treating these individuals with a single treatment regimen, the gap between the current WHO coverage definition and our proposed one is as much as 16% over a 10-year planning horizon. CONCLUSIONS: Cumulative incidence-based definition of coverage yields a more accurate representation of the long-run treatment success and along with the WHO and other definitions of coverage provides a better understanding of the HIV treatment progress.
Authors: R S Braithwaite; S Shechter; M S Roberts; A Schaefer; D R Bangsberg; P R Harrigan; A C Justice Journal: J Antimicrob Chemother Date: 2006-10-05 Impact factor: 5.790
Authors: R Scott Braithwaite; Steven Shechter; Chung-Chou H Chang; Andrew Schaefer; Mark S Roberts Journal: Value Health Date: 2007 May-Jun Impact factor: 5.725
Authors: R Scott Braithwaite; Mark S Roberts; Matthew Bidwell Goetz; Cynthia L Gibert; Maria C Rodriguez-Barradas; Kimberly Nucifora; Amy C Justice Journal: Clin Infect Dis Date: 2009-03-15 Impact factor: 9.079
Authors: R S Braithwaite; J Conigliaro; M S Roberts; S Shechter; A Schaefer; K McGinnis; M C Rodriguez; L Rabeneck; K Bryant; A C Justice Journal: AIDS Care Date: 2007-04
Authors: R Scott Braithwaite; Michael J Kozal; Chung Chou H Chang; Mark S Roberts; Shawn L Fultz; Matthew Bidwell Goetz; Cynthia Gibert; Maria Rodriguez-Barradas; Larry Mole; Amy C Justice Journal: AIDS Date: 2007-07-31 Impact factor: 4.177
Authors: R Scott Braithwaite; Mark S Roberts; Chung Chou H Chang; Matthew Bidwell Goetz; Cynthia L Gibert; Maria C Rodriguez-Barradas; Steven Shechter; Andrew Schaefer; Kimberly Nucifora; Robert Koppenhaver; Amy C Justice Journal: Ann Intern Med Date: 2008-02-05 Impact factor: 25.391
Authors: R Scott Braithwaite; Kimberly A Nucifora; Constantin T Yiannoutsos; Beverly Musick; Sylvester Kimaiyo; Lameck Diero; Melanie C Bacon; Kara Wools-Kaloustian Journal: J Int AIDS Soc Date: 2011-07-30 Impact factor: 5.396